



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 23, 2015

Via E-mail

Dr. Joachim Fleing
Chief Financial Officer and Principal Financial Officer
Sangui Biotech International, Inc.
Alfred Herrhausen Street 44
58455 Witten
Germany

Re: Sangui Biotech International, Inc.
Form 10-K for the Fiscal Year Ended June 30, 2014
Filed September 25, 2014
File No. 000-29233

Dear Dr. Fleing:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Sharon Blume

Sharon Blume
Accounting Branch Chief